Healthcare entity
regulation is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Jim Whittle, the most common co-covered peer. We currently track 1 Healthcare story that mention IDH-mutant astrocytoma and oligodendroglioma, all published on August 2, 2026.
Last mentioned: Aug 2, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
regulation is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Jim Whittle, the most common co-covered peer. We currently track 1 Healthcare story that mention IDH-mutant astrocytoma and oligodendroglioma, all published on August 2, 2026. Each carries 2 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 10 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering IDH-mutant astrocytoma and oligodendroglioma. Shared-story counts are live from our verified record — not editorial picks.
Australia adds vorasidenib to the PBS, cutting monthly costs from $28,000 to a standard co-pay and providing the first targeted therapy in 20 years for IDH-mutant gliomas. The move relieves financial devastation for patients like Leah Ferguson, who can now extend quality time with family. It highlights the government's role in democratizing access to high-cost orphan drugs.
IDH-mutant astrocytoma and oligodendroglioma is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
